Abstract
Objective: This systematic review and meta-analysis is aimed at assessing the risks of cardiovascular adverse events in patients with rheumatoid arthritis (RA) who have been treated with fostamatinib. Methods: The electronic databases of OVID Medline, OVID EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science were searched to identify studies that reported cardiovascular events or hypertension in RA patients treated with fostamatinib. Two reviewers separately and simultaneously screened the retrieved studies based on study selection criteria, collected data and performed methodological quality assessments. The effect size of meta-analysis was estimated by the Peto odds ratio (OR) or relative risk (RR) with 95% confidence intervals (95%CI). Funnel plot was used to estimate publication bias and sensitivity analysis was performed to test the robustness of the results. Results: A total of 12 trials composed of 5,618 participants with low to moderate risk of bias were included. In comparison to the placebo, the use of fostamatinib was found to elevate the risk of hypertension (RR=3.82, 95%CI 2.88–5.05) but was not associated with the risks of all-cause death (Peto OR=0.16, 95%CI 0.02–1.24), major adverse cardiovascular events (Peto OR=1.24, 95%CI 0.26–5.97), pulmonary heart disease and disease of pulmonary circulation (Peto OR=1.23, 95%CI 0.13–11.87), in addition to other forms of heart disease (Peto OR=1.96, 95%CI 0.72–5.38). Furthermore, sensitivity analysis showed no significant change in effective trends and no publication bias was found. Conclusion: Fostamatinib is associated with increased risk of hypertension; however, no increased risks of cardiovascular events were observed. Further well-planned cohort studies with large study populations and longer follow-up times are needed to elucidate the outcomes. Systematic Review Registration: [PROSPERO], identifier [CRD42020198217].
Highlights
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation and autoantibodies, which mainly occurs among members of the population that are over 40 years of age
In comparison to the placebo, the use of fostamatinib was found to elevate the risk of hypertension (RR 3.82, 95% confidence intervals (95%confidence intervals (CIs)) 2.88–5.05) but was not associated with the risks of all-cause death (Peto odds ratio (OR) 0.16, 95%CI 0.02–1.24), major adverse cardiovascular events (Peto OR 1.24, 95%CI 0.26–5.97), pulmonary heart disease and disease of pulmonary circulation (Peto OR 1.23, 95%CI 0.13–11.87), in addition to other forms of heart disease (Peto OR 1.96, 95%CI 0.72–5.38)
Fostamatinib is associated with increased risk of hypertension; no increased risks of cardiovascular events were observed
Summary
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation and autoantibodies, which mainly occurs among members of the population that are over 40 years of age. The prevalence of RA varies on the basis of country, region, and population. It is 1% for adults in developed countries and 0.2–0.34% for the Chinese (Carmona et al, 2010). The pathogenesis of RA is largely unknown. It was reported tumor necrosis factor alpha (TNFα), positioning upstream in the cytokine cascade, played a critical role in RA. Anti-TNFα inhibitors are thought to be potent and effective treatments. Nearly half of RA patients who used the anti-TNFα inhibitors failed to reach remission and needed to switch to another anti-TNFα inhibitor or another biologic (Kaltsonoudis et al, 2019). The most effective therapeutic agents anti-TNFα inhibitors for RA patients failed to alleviate disease; drugs with other targets are needed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
